Loading
A phase 2 trial of Oleclumab, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) is a phase 2 interventional study registered as NCT06606847 by AstraZeneca, with 30 participants enrolled, started 2024-09-24 and due to reach its primary completion in 2026-05-04. Interventions recorded: Oleclumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Oleclumab, Unresectable stage III non-small-cell lung cancer, Durvalumab, AstraZeneca.
Shares Oleclumab, Unresectable stage III non-small-cell lung cancer, AstraZeneca, Non-small-cell lung cancer.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer.